Publications by authors named "Evan Barry"

Claim this Profile
A
Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor.
Casey J Moure, Brandon Vara, Mangeng M Cheng, Christopher Sondey, Eric Muise, Evan R Barry

Mol Cancer Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine.
Evan R Barry, Vladimir Simov, Iris Valtingojer, Olivier Venier

Cells· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activity.
Rhys D O Jones, Mike Grondine, Alexandra Borodovsky, Maryann San Martin, Michelle DuPont, Evan Barry

Br J Pharmacol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST.
Venkatesh Pilla Reddy, Rana Anjum, Michael Grondine, Aaron Smith, Deepa Bhavsar, Evan Barry

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Erica Banks, Michael Grondine, Deepa Bhavsar, Evan Barry, Jason G Kettle

Sci Transl Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors.
Jason G Kettle, Rana Anjum, Evan Barry, Deepa Bhavsar, Crystal Brown

J Med Chem· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HUWE1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation.
Kevin B Myant, Patrizia Cammareri, Michael C Hodder, Jimi Wills, Alex Von Kriegsheim, Evan Barry

EMBO Mol Med· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.
Ryan E Henry, Evan R Barry, Lillian Castriotta, Brendon Ladd, Aleksandra Markovets

Oncotarget· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Brendon Ladd, Anne Marie Mazzola, Teeru Bihani, Zhongwu Lai, James Bradford, Evan Barry

Oncotarget· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Alwin G Schuller, Evan R Barry, Rhys D O Jones, Ryan E Henry, Melanie M Frigault

Clin Cancer Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development.
Evan R Barry, Fernando D Camargo

Curr Opin Cell Biol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restriction of intestinal stem cell expansion and the regenerative response by YAP.
Evan R Barry, Teppei Morikawa, Brian L Butler, Kriti Shrestha, Rosemarie de la Rosa

Nature· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance.
Dawang Zhou, Yongyou Zhang, Hongtan Wu, Evan Barry, Yi Yin

Proc Natl Acad Sci U S A· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
Evan R Barry, Gareth N Corry, Theodore P Rasmussen

Expert Opin Ther Targets· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic regulatory mechanisms during preimplantation development.
Gareth N Corry, Borko Tanasijevic, Evan R Barry, Winfried Krueger, Theodore P Rasmussen

Birth Defects Res C Embryo Today· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ES cell cycle progression and differentiation require the action of the histone methyltransferase Dot1L.
Evan R Barry, Winfried Krueger, Caroline M Jakuba, Eric Veilleux, Dominic J Ambrosi

Stem Cells· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis